Page last updated: 2024-08-24

triazoles and lopinavir

triazoles has been researched along with lopinavir in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's7 (77.78)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Laurence, J1
Kuritzkes, DR1
D'Avolio, A; Fuchs, D; Gisslén, M; Hagberg, L; Svennerholm, B; Verhofstede, C; Watson, V; Yilmaz, A1
Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Galli, A; Gonzalez de Requena, D; Lazzarin, A; Nozza, S; Simiele, M1
Feucht, N; Hadeler, J; Lanzl, I; Loos, D; Schmid, RM; Schwerdtfeger, C; Spinner, CD1
Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Ghisetti, V; Lazzarin, A; Milia, MG; Nozza, S; Simiele, M1
Antinori, A; Bonora, S; Chiappetta, S; De Battista, D; Di Pietro, M; Galli, L; Lazzarin, A; Malnati, M; Mazzotta, F; Nozza, S; Ottou, S; Pogliaghi, M; Ripa, M; Zaccarelli, M1
Arenas-Pinto, A; Benn, P; Brima, N; Clarke, A; Copas, A; Fisher, M; Gilson, R; Hawkins, D; Milinkovic, A; Schembri, G; Williams, A1
Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL1

Trials

3 trial(s) available for triazoles and lopinavir

ArticleYear
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2010, Dec-15, Volume: 55, Issue:5

    Topics: Adult; Albumins; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Central Nervous System Infections; Cross-Over Studies; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immunoglobulin G; Lopinavir; Male; Maraviroc; Middle Aged; Neopterin; Peptide Fragments; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Triazoles; Viral Load; Viremia; Virus Replication

2010
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2015, Volume: 21, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; DNA, Viral; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Maraviroc; Prospective Studies; Ritonavir; Treatment Outcome; Triazoles; Viral Load

2015
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
    The Journal of antimicrobial chemotherapy, 2017, 06-01, Volume: 72, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Maraviroc; Medication Adherence; Post-Exposure Prophylaxis; Ritonavir; Triazoles; Young Adult

2017

Other Studies

6 other study(ies) available for triazoles and lopinavir

ArticleYear
Pivotal moments in HIV treatment: the 14th CROI.
    The AIDS reader, 2007, Volume: 17, Issue:5

    Topics: Anti-Retroviral Agents; Clinical Trials as Topic; Congresses as Topic; Cyclohexanes; HIV Fusion Inhibitors; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Maraviroc; Multicenter Studies as Topic; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles; United States

2007
Report from the XVI International HIV Drug Resistance Workshop.
    AIDS clinical care, 2007, Volume: 19, Issue:8

    Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Lopinavir; Maraviroc; Nitriles; Piperazines; Pyridazines; Pyrimidines; Pyrimidinones; Triazoles

2007
Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:7

    Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Plasma; Ritonavir; Time Factors; Triazoles

2013
[Ophthalmological alterations at the initial diagnosis of HIV infection].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2014, Volume: 111, Issue:7

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Early Diagnosis; Emtricitabine; Eye Infections, Viral; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Organophosphonates; Retinal Diseases; Syndrome; Tenofovir; Treatment Outcome; Triazoles; Zidovudine

2014
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:9

    Topics: Adult; Anti-HIV Agents; Cyclohexanes; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Middle Aged; Plasma; Ritonavir; Semen; Triazoles

2014
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.
    Journal of neurovirology, 2017, Volume: 23, Issue:6

    Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine

2017